← Back to Search

Intravenous Ketamine for Major Depressive Disorder

Phase 3
Waitlist Available
Led By Pierre Blier, MD, PhD
Research Sponsored by University of Ottawa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-4 weeks
Awards & highlights

Summary

This trial compares intravenous ketamine to electroconvulsive therapy (ECT) for patients with depression who haven't responded to other treatments. Ketamine is given through an IV and works quickly to improve mood. The study aims to show that ketamine works faster, has fewer side effects, and is less costly than ECT. Ketamine has been found to elicit a rapid antidepressant response in repeated doses and may improve neurocognitive functioning.

Eligible Conditions
  • Depression
  • Major Depressive Disorder
  • Depression, Bipolar Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Montgomery-Asberg Depression Rating Scale

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intravenous KetamineExperimental Treatment1 Intervention
Group II: Electroconvulsive TherapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

Ontario Shores Centre for Mental Health SciencesOTHER
12 Previous Clinical Trials
1,898 Total Patients Enrolled
Queen's UniversityOTHER
369 Previous Clinical Trials
121,638 Total Patients Enrolled
University Health Network, TorontoOTHER
1,492 Previous Clinical Trials
489,804 Total Patients Enrolled
~40 spots leftby Dec 2025